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Abstract Anemia of chronic disorders is a very important
phenomenon and iron is a crucial factor of this complex pro-
cess. To better understand this process and its inﬂuence on
some other factors we have built a mathematical model of the
human body iron homeostasis, which possibly most exactly
would reﬂect the metabolism of iron in the case of anemia and
inﬂammation. The model has been formulated in the language
of Petri net theory, which allows for its simulation and precise
analysis. The obtained results of the analysis of the model’s
behavior,concerningtheinﬂuenceofanemiaandinﬂammation
on the transferrin receptors, and hepcidin concentration chan-
ges are the valuable complements to the knowledge following
from clinical research. This analysis is one of the ﬁrst attempts
to investigate properties andbehavior of a not fullyunderstood
biological system on a basis of its Petri net based model.
Keywords Iron   Hepcidin   Inﬂammation   Modeling  
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Introduction
Iron balance is tenuous, and both iron deﬁciency and iron
overload are deleterious. Iron homeostasis is orchestrated
at the cellular as well as at the systemic level [1]. At the
cellular level, iron homeostasis is aimed at controlling the
iron uptake, storage and export as well as the intracellular
iron management and distribution. At the systemic level,
iron homeostasis aims to meet the erythroid demands and
keep the iron stores replete. The recent discovery of hep-
cidin (the iron regulatory hormone) has provided a con-
sistent model of the iron homeostasis that allows for a
better understanding of the importance of sensors at the
cellular level for iron needs, as well as of the pathophysi-
ology of the hereditary iron metabolism disorders such as
hemochromatosis and anemia of chronic disorders (ACD).
Iron deﬁciency is by far the most common hematolog-
ical disorder encountered in general practice. The basic
approach to its diagnosis and management is well estab-
lished and outlined in most medical and hematological
texts. However, the patients suffering from anemia very
often are affected by other additional medical problems,
such as bacterial and viral infections, an inﬂammation or
malignant tumors. Thus, an assessment of the body iron
status seems to be more complex issue. Such conditions
mentioned above exhibit a blunted erythropoietin (EPO)
response by erythroid precursors, a decreased red blood
cell survival, abnormalities in both iron absorption and the
retention of iron in the one-nuclear cells, and they restrict
the availability of iron to the erythroid precursors in the
bone marrow.
ACD is a common problem particularly in patients with
end-stage renal disease and it is present in a vast majority
of patients treated with maintenance hemodialysis. The
immunological basis of an inﬂammatory process in dialysis
was presented among others in [2–4].
Fortunately, the renal anemia has been shown to be
effectively alleviated or reversed by recombinant human
erythropoietin (rHuEPO) which increases the speed of
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poietic activity would require a twofold iron demand. In
such a state, the iron turnover will be a function of the iron
stores and the erythropoietic activity of the bone marrow.
The assessment of the iron requirements and an adequate
iron supply are a prerequisite to an optimal response to
rHuEPO.
A number of laboratory tests are employed to determine
the iron status in patients receiving rHuEPO therapy,
however, a valid method for the diagnosis of an iron
deﬁciency anemia is still debatable. The iron availability
may not keep pace with the iron demand for rHuEPO-
enhanced erythropoiesis. This situation is known as a
functional iron deﬁciency.
Because of the complexity of this issue, our emphasis in
this article is put on the better understanding of the phe-
nomenon of ACD and its diagnosis. For this purpose, we
built a model of the body iron homeostasis formulated in
the language of Petri net theory, which is precise enough
for a possible analysis and allows a simulation of the
process. A Petri net is a well-known mathematical struc-
ture, which has found many applications in the analysis of
technical systems of many types. The concept of Petri nets
was proposed in the early 1960s by Carl A. Petri [6] in the
area of technical systems as formalism suitable for mod-
eling and the analysis of concurrent, asynchronous, dis-
tributed systems. With a rapid growth of computational
biology in the last decade of the twentieth century, the
structure of Petri nets was also used to model biological
systems [7]. Since that time, Petri nets are being used for
describing and analyzing various biological processes, e.g.,
metabolic pathways [8], signal transduction pathways [9],
and gene-regulatory networks [10]. For an overview of the
biological applications see, e.g., [11, 12]. Generally, the
advantages of using Petri nets for the required model are on
the one hand their feature to represent the system behavior
even when the biological process is not understood in every
detail by combining different abstraction levels in one
model [13]. And on the other hand, Petri nets comprise
besides their ﬁrm mathematical foundation a visual repre-
sentation of the model which enables a simulation of the
system facilitating an intuitive comprehension of the bio-
logical pathways [14].
In the following, a very brief introduction to the Petri net
theory is given. A more detailed overview of the theory can
be found in [15, 16].
A Petri net is a directed graph composed of two kinds
of nodes and arcs connecting some of them but only
nodes of different types can be connected in this way. One
kind of nodes is given by the places which model the
passive system components like states or biological species
and they are represented by circles. The second kind of
nodes is called transitions standing for the active system
components as events or biological reactions, which in
graphical representation are depicted as rectangles. Thus,
the net arcs describe the interaction between the active and
the passive system elements. Besides these structural ele-
ments, a Petri net has an additional dynamic component
given by tokens, which can ﬂow through the net. Generally,
the tokens reside in places indicating that the correspond-
ing state is fulﬁlled or, in a biological context, the corre-
sponding substance is present in the system. A possible
token ﬂow is deﬁned by the net structure. According to the
arc direction every place (transition) may have a set of pre-
and post-transitions (pre- and post-places). If all pre-places
of a transition are marked with tokens, this transition is
enabled to ﬁre, i.e., the corresponding event or reaction
may take place if all its reactants or other necessary
chemical substances are available. With its ﬁring the
transition removes tokens from all its pre-places and puts
tokens to all its post-places, i.e., the reaction removes a
token of each its precursors and produces a token of each
its products, since the tokens indicate the presence of the
substance. In general, the number of moved tokens depends
on the corresponding arc weight. But with relation to the
model presented in this paper, we consider only ordinary
Petri nets, i.e., all arcs are weighted with one. Altogether,
arcs connect an event with its pre-conditions, which must
be fulﬁlled to trigger this event and with its post-condi-
tions, which will be fulﬁlled by occurring of that event. A
transition without pre-places, a so-called input transition, is
not determined by the tokens of the net and thus the event
modeled by an input transition may take place at every
time. In the case that a condition must be fulﬁlled but the
ﬁring of an adjacent transition does not remove any tokens
from the corresponding place, these nodes are connected
via two converse arcs. In the model, they are represented
by bi-directional arrows and are called read arcs. Gener-
ally, a place in a Petri net may carry any integer number of
tokens, indicating different degrees of fulﬁllment or dif-
ferent quantities of the corresponding substance. Since the
number of pre-places of a transition has not to be equal to
the numbers of its post-places, the total number of tokens
in the net is not conserved. The distribution of the tokens
over all places is called the marking of the net and
describes a certain system state. Correspondingly, the ini-
tial marking represents the system state before the ﬁring of
any transition.
Materials and methods
The model
To develop the Petri net model, at ﬁrst all relevant bio-
logical interactions are translated into basic logical terms as
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123implication, conjunction, disjunction, and negation. These
logical terms are then unambiguously transformed into
Petri net components. The graphical representation of a
small Petri net example given in Fig. 1 serves as an illus-
tration. A conjunction-coupled implication is given with
p0 ^ p1 ) p2, i.e., only if the places p0 and p1 are
marked transition t2 may ﬁre. Its ﬁring puts a token at place
p2. The two post-transitions of place p2, t3, and t4, are in
conﬂict, i.e., one token at place p2 may enable both of
these transitions but only one of them can ﬁre. The ﬁring of
t3 additionally depends on the marking of place p5. If p5i s
not marked, a token on place p2 leads to the ﬁring of
transition t4 (as the only enabled post-transition), i.e.,
p2 ^: p5 ) p4. If there is a token on p5, a non-deter-
ministic behavior results since the corresponding subnet
represents an exclusive disjunction, i.e., p2 ^ p5 )
p3   p4.
Finally, an assembling of subnets built in that way
gives the model. If there are some places without pre- or
post-transitions in the net, some additional transitions are
included representing the interface of the biological sys-
tem to its surrounding (compare transitions t0, t1, t7, and
t8 in Fig. 1). This modeling approach is introduced in
[17].
According to this approach, a Petri net is built modeling
the body iron homeostasis. This model contains 47 places
(p) and 57 transitions (t), shown in Fig. 2. For the sake of
clarity, nodes are only named with their IDs. The corre-
sponding names of the places and transitions are listed in
Tables 1 and 2 [18], respectively, and they are self-
explanatory formulated.
Our model has been precisely described recently in
[18, 19] and with using the time intervals in [20]. In the
presented model, we took into consideration the fact that
anemia associated with a chronic inﬂammatory state is
multi-factorial. During an inﬂammation, the body iron
metabolism is changing. Iron is indispensable to living
organisms; in vitro it is also conducive to bacterial growth
[21]. Some bacteria, in fact, have an iron uptake system
that allows for the direct uptake of iron by means of a
surface TfR. Within this context, no free iron is available in
the circulation to promote the replication of microorgan-
isms [22]. In vivo, a number of mechanisms exist to limit
the bacterial use of iron, notably an iron uptake via the
reticuloendothelial system (the one-nuclear cells). So, an
infectious and inﬂammatory disease commonly results a
low serum iron concentration, which in consequence may
lead to anemia.
Recently, it was found that hepcidin, a protein whose
production is modulated in response to an inﬂammation,
anemia, and hypoxia, is a link between anemia and
inﬂammation [23]. Hepcidin, by binding to ferroportin
(Fpn), appears to block the iron uptake in the small intes-
tine and the release from the one-nuclear cells thereby
decreasing the delivery of iron to the red blood cells pre-
cursors in the bone marrow [24].
In our model, a part of the network including corre-
lations between the body iron and an inﬂammatory pro-
cess was based on the Frazer and Anderson hypothesis
[25]. According to this, the regulation of the hepcidin
expression depends on the ratio of transferrin receptor 1
(TfR1) on the one-nuclear cells’ surface to the HoloTf
(Fe
3?) concentration in the serum. Hepatocyte surface
HFE (the hemochromatosis protein) competes with Ho-
loTf (Fe
3?) for the binding on surface TfR1, which is a
TfR2 competitor. Unbound surface HFE and a higher
concentration of the HoloTf (Fe
3?) TfR2 complex
increase the hepatic hepcidin expression and its release.
According to this model, an iron deﬁciency would lead to
a decrease of the circulating HoloTf (Fe
3?), and the
concentration of free surface TfR1s would increase,
resulting in a decreasing fraction of the free surface HFE
and in a lower concentration of the HoloTf (Fe
3?) TfR2
complex. This has been modeled in following way:
HoloTf (Fe
3?) ? TfR2 (t47) leads via free HFE to a
hepcidin increase (t48) that leads to a decrease of Fpn
(t36). A too small amount of Fpn avoids the iron transport
out of the small intestine (t11) as well as the iron trans-
port out of the one-nuclear cell (t28). If the iron level is
low, there is more TfR1 than TfR2 (t46) and, therefore,
there is no free HFE. In the model, the iron release out of
the ferritin-connected store requires that there is no
inﬂammation in the system (t32 in the one-nuclear cell
and t44 in the small intestine).
The analysis of the model
The developed model has to be veriﬁed by an analysis of
the net. A general overview of analysis possibilities is
Fig. 1 A small Petri net containing seven places and nine transitions
serving as an example. Input and output transitions are depicted as ﬂat
rectangles. The token of the initial marking is depicted by the dot on
the place. For more details about it, its p-invariant and its three
t-invariants, please see the text
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123given, e.g., in [13, 25, 26]. Further explanations for the
analysis of this particular Petri net model are given in
[18, 27].
At ﬁrst, some structural properties are calculated based
on the net structure. A main part of the further model
validation consists in the invariant analysis based on the
incidence matrix [28]. Each entry of this (place 9 transi-
tion) matrix C gives the token change on a particular place
by ﬁring of the respective transition. Thus, no information
about node connections via read arcs is included in C. The
transition matrix for the simple net shown in Fig. 1 is as
follows (rows correspond to places and columns corre-
spond to transitions):
C ¼
10 1 000000
01 1 000000
00 1  1  10 0 0 0
0 0 01000  10
0 0 001000  1
00 0 0 0  11 0 0
0 0 0001  10 0
2
6 6 6 6 6 6 6 6 4
3
7 7 7 7 7 7 7 7 5
A p-invariant is calculated as a vector y satisfying the
equation y  C = 0 and it is called a minimal p-invariant if it
does not contain any other p-invariant. Such an invariant
provides a set of places over which the weighted sum of
tokens is constant. As a clear example, consider the Petri
t2
p2
t1
p1
t0
p0
t7
p8
t6
t8
p7
t9
t10
p40
t54
p4 t51 p5 t52 p6
p42
t35
p32
p46
t36
p43
p4
p23 t45
p6
t46 p36
p37
p4
t3
p3
t4 t5
p5 p6
t44
p35 p6 t12
p45
p30
t11 p32
p9
t13
p10
p15 t16 t15
t14 p6
p5
p4
p37
t47
p38 p15
p11
t17
p12
t19
p13
t18
p15 p23 p23 p15
p39
t53
p14
t20
p16
t38
p34
p17
t21 p33 t37 p5
p6
t39
p34 p33
t41
t22
p18 t23 p19 t24 p20
t33 p4
p29
p6 p35
p44
t56
p10
p23 t27
p22
t25
p21
t26
p20
p6
p32
p31
t34
p10
t42
p35
t43
p28
t55
p41
t31
p27
t29
p24 p15 t49
t50
p43 t30
t48
p38 p26
t40
p42
p34
p25
p23
t28
t32
iron uptake
small intestine
(pre-) erythrocyte
inflammatory process
one-nuclear cell
Fpn regulation
TfR regulation
hepcidin regulation
Fig. 2 The Petri net modeling
the body iron homeostasis.
Nodes are labeled with their
IDs; their corresponding names
are listed in Table 1, and
Table 2, respectively. Logical
places are tinted in grey and
avoid immoderate arc crossing.
A logical node is deﬁned by its
ID and exists in multiple copies
in the net, which are logically
identical. Thus, this model is a
connected Petri net. Functional
or spatial subunits are marked
by accordingly labeled ellipses
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123net in Fig. 1. It has one minimal p-invariant given by the
vector (0, 0, 0, 0, 0, 1, 1), i.e., the places p5 and p6 form
such an invariant and, therefore, the token placed on p6i n
the initial marking circulates only between those two pla-
ces (by ﬁring of transitions t5 and t6). A required number
of tokens (here one) has to be put in the initial marking at a
place of each p-invariant to ensure that this subnet may
contribute to the system behavior.
The iron homeostasis model contains four minimal
p-invariants. Hence, the places Fe serum medium (p5),
Much Fpn (p32), Less hepcidin (p25), and TfR1 (p23) are
marked with tokens already in the initial marking. Note
that the tokens are put at one place of each p-invariant in a
way representing an inactive state of the model. That
means a medium level of iron, a high level of Fpn, a low
level of hepcidin, and a higher amount of TfR1 compared
with the amount of TfR2 is assumed to be the physiolog-
ically normal state of the system. These tokens contained in
the initial marking of the net will circulate only between
places of each minimal p-invariant. For example, the ﬁrst
p-invariant consists of the places Fe serum high (p4), Fe
serum medium (p5), and Fe serum low (p6). Thus, the
mentioned token will only circulate between those three
places, indicating the level of iron in the serum. The second
and the third minimal p-invariants, both consist of two
places, which are less hepcidin (p25) and much hepcidin
(p26), and much Fpn (p32), and less Fpn (p46), respec-
tively. Each of the two tokens circulating between those
places indicates the changed available quantity of hepcidin
and Fpn, respectively. The fourth minimal p-invariant
indicates by its token the form in which TfR1 is present in
the system. It contains the six places HoloTf (Fe
3?) ?
TfR1 (p12), ApoTf ? TfR1 (p13), ApoTf ? TfR1 (p21),
HoloTf (Fe
3?) ? TfR1 (p22), TfR1 (p23), and less TfR1
(p36). To distinguish these places see Fig. 2.
The minimal t-invariants of a net are calculated as
vectors x satisfying the equation C   x = 0 and not con-
taining any other such a vector and give a multiset of
transitions which have altogether a zero effect on the
marking, i.e., if all of them have ﬁred the required number
of times, a given marking is reproduced. Since the initial
marking stands for that system state assumed as the normal
state of the body, the t-invariants are a set of processes
which lead again to that normal state after iron has been
absorbed or other reactions have taken place.
The example net shown in Fig. 1 again should serve as
an illustration. It has three minimal t-invariants: given by
vectors (0, 0, 0, 0, 0, 1, 1, 0, 0), (1, 1, 1, 1, 0, 0, 0, 1, 0), and
(1, 1, 1, 0, 1, 0, 0, 0, 1). It means that the ﬁrst of them
contains the transitions t5 and t6 (representing the above-
mentioned circulation of the token in the p-invariant). The
second one consists of t0, t1, t2, t4, and t8 and the third
minimal t-invariant includes t0, t1, t2, t3, and t7. The latter
one is not feasible since it takes not into account the read
arc between t3 and the empty place p5. A feasible
t-invariant is a minimal t-invariant such that all transitions
not belonging to this invariant. The reason that a minimal
t-invariant is not a feasible t-invariant is an occurrence of
read arcs, which are not reﬂected in the net incidence
matrix (cf. [17, 18]). Thus, a processing of the minimal
t-invariants combines these ones containing such connec-
tions with invariants providing tokens at these places see
[17]. This combination leading to feasible t-invariants
results for the example net in the t-invariants: ﬁrstly, t5 and
t6, secondly, t0, t1, t2, t4, and t8, and thirdly, t0, t1, t2, t3,
t5, t6, and t7.
Since every possible invariant (i.e., p- and t-invariant)
can be built as non-negative linear combination of minimal
Table 1 The names and IDs of the places of the model
ID Place name ID Place name
0 LIP (in the small intestine) 24 IL-6 (cytokine)
1 Hem (Fe
2?) in the small
intestine
25 Less hepcidin
2 Hem (Fe
2?) 26 Much hepcidin
3 Ferritin (Fe
3?) 27 Much HAMP protein
4 Fe serum high 28 Inﬂammatory process
5 Fe serum medium 29 Ferritin (Fe
3?)
6 Fe serum low 30 Available Fe
2?
7F e
3? 31 Fe
2? in serum (the one-
nuclear cell)
8F e
2? 32 Much Fpn
9F e
2? in serum 33 Erythrocyte synthesis support
10 Fe
3? in serum 34 Much EPO
11 HoloTf (Fe
3?) 35 No inﬂammatory process
12 HoloTf (Fe
3?) ? TfR1 36 Less TfR1
13 ApoTf ? TfR1 37 TfR2
14 LIP in pre-erythrocyte 38 Free HFE
15 ApoTf 39 Fe
2?
16 Hem (Fe
2?)4 0 F e
3?
17 Erythrocyte 41 Much HFE protein
18 Hem (Fe
2?) in the one-
nuclear cell
42 Positive Fpn signal
19 Free Fe
2? 43 Negative Fpn signal
20 LIP 44 Fe
2? in serum (one-nuclear
cell)
21 ApoTf ? TfR1 45 Mitochondrium/enzymes
22 HoloTf (Fe
3?) ? TfR1 46 Less Fpn
23 TfR1
Some of these places are equally named (e.g. p8 and p39), but they
are identiﬁed as different nodes, because they were not deﬁned as
logical nodes [18]
LIP labile iron pool, HoloTf holotransferrin, ApoTf apotransferrin, IL-
6 interleukin-6, HAMP hepcidin antimicrobial peptide, Fpn ferro-
portin, TfR, TfR1, TfR2 transferrin receptors, EPO erythropoietin,
HFE the hemochromatosis protein
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123invariants in most cases it is sufﬁcient to consider only the
minimal ones. So, in our analysis only the minimal
invariants are taken into account. Moreover, we focused on
minimal t-invariants, since the analysis of them gives the
most interesting biological results (at least in the case of
our system).
In the model of the human body iron homeostasis, a
processing of the 45 minimal t-invariants of the net leads to
85 feasible t-invariants. A speciﬁcation of the feasible
t-invariants can be found in Table 4. The model is covered
by feasible t-invariants, i.e., each transition is contained in
such a t-invariant. Therefore, each modeled event takes
place in the basic behavior of the net since the feasible
t-invariants characterize this behavior [17, 28]. For the
purpose of model veriﬁcation, it has been checked and at
last conﬁrmed that each feasible t-invariant has a biological
equivalent, see [18].
Based on the feasible t-invariants it is decidable for each
pair of transitions if they occur only together with each
other in all of the feasible t-invariants or, if that is not the
case, if they occur only in different feasible t-invariants.
Following this information, the so-called MCT sets are
built which consist of the processes linked with each other.
In other words, the MCT-sets are calculated in such a way
that two transitions belong to the same set if and only if
they are elements of exactly the same feasible t-invariants.
Transition which is not contained in any t-invariant form a
single-element MCT-set. These sets support the veriﬁca-
tion of a biological meaning of feasible t-invariants (cf.
[17, 18]). The MCT sets can be determined using the fol-
lowing simple algorithm:
Step 1. Compute I(ti), i.e., sets of t-invariants that
share transition ti, for all t-invariants ti, e.g., create
Table 2 The names and IDs of
the transitions of the model [18]
HO heme oxygenase, LIP labile
iron pool, IRP iron responsive
protein, DMT1/NRAMP2/DCT1
divalent metal transporter-1
(natural resistance-associated
macrophage protein-2 or
divalent cation transporter-1),
Dcytb duodenal cytochrome b,
Heph hephaestin, ApoTf
apotransferrin, RME receptor-
mediated endocytosis, TfR,
TfR1, TfR2 transferrin receptors,
Nramp1 natural resistance-
associated macrophage protein-
1, IL-6 interleukin-6, HAMP
hepcidin antimicrobial peptide,
Cp ceruloplasmin, Fpn
ferroportin, EPO erythropoietin,
HoloTf holotransferrin, HFE the
hemochromatosis protein
ID Transition name ID Transition name
0 Oxygenation via HO 29 IL-6 increase
1 Transport into the small intestine (transporter X) 30 Hepcidin increase (expressed in the liver)
2 Hem (Fe
2?) uptake 31 HAMP expression
3 LIP split (IRP inactive) 32 (Fe
2?) release
4 LIP split 33 Store (apoferritin) (IRP)
5 LIP split (IRP active) 34 Oxidation (Cp)
6 Transport into the small intestine
(DMT1/NRAMP2/DCT1)
35 Fpn increase
7 (Fe
2?) uptake 36 Fpn decrease/inhibition
8 Reduction by HCL 37 Positive signal
9 (Fe
3?) uptake 38 Erythrocyte synthesis
10 Reduction by Dcytb 39 Signal for EPO synthesis in the kidneys
11 Transport out of the small intestine 40 Hepcidin inhibition
12 Loss 41 EPO decrease
13 Oxidation (Heph) 42 Normal state
14 Increase of low serum Fe level 43 Inﬂammatory process
15 Increase of medium serum Fe level 44 Fe
2? release
16 Binding of ApoTf ? Fe
3? 45 TfR1 inhibition (RNA degradation via IRP)
17 Endocytosis in pre-erythrocyte (RME) (TfR1) 46 TfR1 synthesis (RNA stabilization via IRP)
18 Exocytosis ? cleavage 47 HoloTf (Fe
3?) ? TfR2
19 Cleavage by low pH 48 Hepcidin increase (expressed in the liver)
20 Hem synthesis (ferrochelatase and
protoporphyrin IX)
49 Apo Tf synthesis
21 Erythrocyte synthesis 50 Apo Tf synthesis inhibition
22 Phagocytosis in the one-nuclear cell 51 Fe consumption
23 Oxygenation 52 Fe consumption
24 Transport via Nramp1 53 Transport into cytosol
(DMT1/NRAMP2/CDT1)
25 Cleavage by low pH 54 (Fe
3?) uptake parenteral
26 Exocytosis ? cleavage 55 HFE expression
27 Endocytosis in the one-nuclear cell (RME)(TfR1) 56 Oxidation (Cp)
28 Transport out of the one-nuclear cell
586 Bioprocess Biosyst Eng (2011) 34:581–595
123empty set for each transition and add t-invariants by
iteration over all transitions feasible t-invariants.
Step 2. Group equal sets I(ti), e.g., sort these sets
lexicographically.
Step 3. Create MCT-sets corresponding to grouped
sets obtained in Step 2, if a set is empty, then cor-
responding transition creates separate MCT-set.
Example: if the result of Step 1 is: I(t1) = {y2, y3, y7},
I(t2) = {y1, y3, y7}, I(t3) = {y2, y3, y7}, I(t4) = {y1, y3, y7},
I(t5) = {y2, y3, y7}, I(t6) = [, I(t7) = [, …, I(t|T|) = [,
where yi is a feasible t-invariant and |T| is the number of
transitions, then the result of Step 2 is: G = {{I(t1), I(t3),
I(t5)}, {I(t2), I(t4)}, I(t6), I(t7), …, I(t|T|)} and the result of
Step 3 is: MCT1 = {t1, t3, t5}, MCT2 = {t2, t4}, MCT3 =
{t6}, MCT4 = {t7}, …,M C T |G| = {t|T|}.
The MCT-sets of the example net in Fig. 1 should
illustrate this grouping of transitions. Here, the net contains
four MCT-set. They are given after an examination of the
three feasible t-invariants named in the text above. Thus,
the sets are: MCT-set 1 = {t5, t6}; MCT-set 2 = {t0, t1,
t2}; MCT-set 3 = {t3, t7}; MCT-set 4 = {t4, t8}. The
invariants can, therefore, be expressed in terms of MCT-
sets. Generally, the transitions remaining as single once
after the grouping mentioned above, represent the so-called
trivial MCT-sets. In the following, they will be named as
single transitions.
The MCT-sets of the homeostasis model are given in
Table 3. They are used also for Table 4 listing the feasible
t-invariants (in this table the transitions composing each
invariant and MCT-sets whose element a given invariant is
also listed).
Based on the information given in Table 4,i ti s
deducible which of the biological processes are indepen-
dent of each other. In order to epitomize the information
about the feasible t-invariants in a more compact way, the
feasible t-invariants are grouped based on their similarities
in the so-called t-clusters [29]. Figure 3 [18] gives the
dendrogram of the ten t-clusters of the 85 feasible
t-invariants built using various clustering approaches. The
dendrograms shown in parts (a)–(d) of the ﬁgure are results
of application of standard clustering approaches, i.e., UP-
GMA-based approach and with an accordance of 65%,
complete linkage with Euclidean distance metric, single
linkage with percent disagreement metric and weighted
pair group average with Euclidean distance metric,
respectively. Clusters obtained using UPGMA method
have been a base for grouping clusters obtained with the
three remaining approaches, i.e., accordance in these
approaches have been adjusted for clusters shown in part
(a) for a comparison of the results. In addition, in part (e) of
Fig. 3 there is shown a dendrogram obtained using some
non-standard clustering approach, which we call pathway-
based approach, where feasible t-invariants having the
same starting and ending transitions are considered as
elements of the same cluster. As it can be noticed, the
dendrograms shown in parts (a)–(d) of the ﬁgure are very
similar to each other. The clusters obtained in all these
cases are the same and the hierarchies differ not
considerable.
The most important conclusion following from these
results is that various classical clustering methods give the
same t-clusters which can be used for an analysis of the
biological properties of the net.
Part (e) of Fig. 3 shows the results of a clustering which
are considerably different from those shown in parts
(a)–(d). First of all, the number and the composition of the
clusters differ from the previous one. The clusters hierar-
chy is also different. The reason is that the applied clus-
tering procedure is based on a completely different idea.
Table 3 The MCT-sets of the
model and their biological
meaning
LIP labile iron pool, IL-6
interleukin-6, EPO
erythropoietin, Fpn ferroportin,
TfR transferrin receptor, HFE
hemochromatosis protein
MCT-set Contained transitions Biological meaning
1 0, 1, 2 Hem(Fe
2?) uptake
2 4, 11, 12, 13, 14, 44, 52 Iron transport through the small intestine
3 5, 15, 51 Iron level changes from low to high and decreases again
4 8, 9 (Fe
3?) uptake
5 10, 54 Parenteral (Fe
3?) uptake
6 17, 18, 19, 20, 22, 23, 24, 53 Iron pathway through the erythrocyte
7 25, 26, 27 Iron pathway through the one-nuclear cell
8 28, 34 Iron from the LIP to the serum
9 29, 43 Inﬂammation and IL-6 increase
10 30, 31, 55 Inﬂammation caused increase of hepcidin
11 32, 33, 56 Iron from LIP to store and its release
12 35, 36, 40 Hepcidin decrease caused by much EPO, Fpn increase
13 45, 46, 47, 48 TfR2 and free HFE caused hepcidin increase
14 49, 50 ApoTf decrease caused by IL-6 increase
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the t-clusters obtained with this method and also corre-
sponding input and output transitions. They are the starting
and ending transitions of a feasible t-invariant, on which
the grouping procedure is based. Table 6 contains a com-
parison of the results of pathway-based clustering and the
classical approaches. There are shown the numbers of
common feasible t-invariants for all pairs of classical and
non-classical t-clusters.
Table 4 The feasible t-invariants of the model
t-cluster Feasible
t-invariant
MCT-sets Transitions
1 61 2, 3, 5, 6, 11 3, 6, 16, 38, 39, 42
60 2, 3, 5, 6, 11 6, 16, 38, 39, 42
59 2, 3, 4, 6, 11 3, 6, 16, 38, 39, 42
58 2, 3, 4, 6, 11 6, 16, 38, 39, 42
57 2, 3, 6, 11 3, 6, 7, 16, 38, 39, 42
56 2, 3, 6, 11 6, 7, 16, 38, 39, 42
49 2, 3, 5, 6, 11 3, 6, 16, 21, 37, 42
48 2, 3, 5, 6, 11 6, 16, 21, 37, 42
47 2, 3, 4, 6, 11 3, 6, 16, 21, 37, 42
46 2, 3, 4, 6, 11 6, 16, 21, 37, 42
45 2, 3, 6, 11 3, 6, 7, 16, 21, 37, 42
44 2, 3, 6, 11 6, 7, 16, 21, 37, 42
55 1, 2, 3, 6, 11 3, 16, 38, 39, 42
54 1, 2, 3, 6, 11 16, 38, 39, 42
43 1, 2, 3, 6, 11 3, 16, 21, 37, 42
42 1, 2, 3, 6, 11 16, 21, 37, 42
2 65 2, 3, 5, 6, 8 3, 6, 16, 38, 39, 42
64 2, 3, 4, 6, 8 3, 6, 16, 38, 39, 42
63 2, 3, 6, 8 3, 6, 7, 16, 38, 39, 42
53 2, 3, 5, 6, 8 3, 6, 16, 21, 37, 42
52 2, 3, 4, 6, 8 3, 6, 16, 21, 37, 42
51 2, 3, 6, 8 3, 6, 7, 16, 21, 37, 42
21 2, 5, 6, 8 6, 16, 38, 39, 42
20 2, 4, 6, 8 6, 16, 38, 39, 42
19 2, 6, 8 6, 7, 16, 38, 39, 42
17 2, 5, 6, 8 6, 16, 21, 37, 42
16 2, 4, 6, 8 6, 16, 21, 37, 42
15 2, 6, 8 6, 7, 16, 21, 37, 42
62 1, 2, 3, 6, 8 3, 16, 38, 39, 42
50 1, 2, 3, 6, 8 3, 16, 21, 37, 42
18 1, 2, 6, 8 16, 38, 39, 42
14 1, 2, 6, 8 16, 21, 37, 42
3 85 2, 3, 5, 12, 13 6, 16, 39, 42
84 2, 3, 5, 12, 13 3, 6, 16, 39, 42
83 2, 3, 4, 12, 13 6, 16, 39, 42
82 2, 3, 4, 12, 13 3, 6, 16, 39, 42
81 2, 3, 12, 13 6, 7, 16, 39, 42
80 2, 3, 12, 13 3, 6, 7, 16, 39, 42
79 1, 2, 3, 12, 13 16, 39, 42
78 1, 2, 3, 12, 13 3, 16, 39, 42
4 41 2, 3, 5, 9, 10, 12 3, 6, 39, 42
40 2, 3, 4, 9, 10, 12 3, 6, 39, 42
39 2, 3, 9, 10, 12 3, 6, 7, 39, 42
13 2, 5, 9, 10, 12 6, 39, 42
12 2, 4, 9, 10, 12 6, 39, 42
11 2, 9, 10, 12 6, 7, 39, 42
38 1, 2, 3, 9, 10, 12 3, 39, 42
10 1, 2, 9, 10, 12 39, 42
Table 4 continued
t-cluster Feasible
t-invariant
MCT-sets Transitions
5 7 3 2 ,3 ,5 ,7 ,1 1 3 ,6 ,1 6 ,4 2
72 2, 3, 5, 7, 11 6, 16, 42
71 2, 3, 4, 7, 11 3, 6, 16, 42
10 2, 3, 4, 7, 11 6, 16, 42
69 2, 3, 7, 11 3, 6, 7, 16, 42
68 2, 3, 7, 11 6, 7, 16, 42
67 1, 2, 3, 7, 11 3, 16, 42
66 1, 2, 3, 7, 11 16, 42
6 77 2, 3, 5, 7, 8 3, 6, 16, 42
76 2, 3, 4, 7, 8 3, 6, 16, 42
75 2, 3, 7, 8 3, 6, 7, 16, 42
25 2, 5, 7, 8 6, 16, 42
24 2, 4, 7, 8 6, 16, 42
23 2, 7, 8 6, 7, 16, 42
74 1, 2, 3, 7, 8 3, 16, 42
22 1, 2, 7, 8 16, 42
7 37 2, 3, 5 3, 6, 37, 39, 41, 42
36 2, 3, 4 3, 6, 37, 39, 41, 42
35 2, 3 3, 6, 7, 37, 39, 41, 42
33 2, 3, 5 3, 6, 42
29 2, 3, 5 6, 42
32 2, 3, 4 3, 6, 42
28 2, 3, 4 6, 42
3 1 2 ,3 3 ,6 ,7 ,4 2
27 2, 3 6, 7, 42
8 9 2, 5 6, 37, 39, 41, 42
5 2, 5 6, 42
8 2, 4 6, 37, 39, 41, 42
7 2 6, 7, 37, 39, 41, 42
4 2, 4 6, 42
3 2 6, 7, 42
9 34 1, 2, 3 3, 37, 39, 41, 42
30 1, 2, 3 3, 42
26 1, 2, 3 42
6 1, 2 37, 39, 41, 42
21 , 2 4 2
10 1 9, 14 42
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(e)
Fig. 3 Dendrograms and comparison of clustering methods. Numbers
on the right indicate the number of cluster. In parts a–d, there are the
same t-clusters 1–10 listed in Table 4—these clusters were computed
using classical clustering methods based on size of common transition
subsets. Clusters obtained in part a became a base for grouping
clusters in b–d (accordance in b–d was adjusted for clusters obtained
in a for better comparison of hierarchy); a UPGMA-based clustering
with an accordance of 65%, b complete linkage with Euclidean
distances metric, c single linkage with percent disagreement metric,
d weighted pair group average with Euclidean distances metric. All
clustered t-invariants were represented as 57-dimensional vectors
(transitions 0-56) where each position is equal to 0 or 1 depending on
existence of a transition in given feasible t-invariant. In part e, there
are 9 clusters obtained from pathway-based method with transitions
listed in Table 5. Each cluster was represented as 9-dimensional
vector (6 different input transitions and 3 different output transitions)
where each position is equal to 0 or 1 depending on existence of input/
output transition in given cluster
Table 5 List of t-invariants in clusters obtained from pathway-based clustering (all feasible t-invariants in a cluster have the same sets of input
and output transitions)
T-cluster Feasible t-invariant Input transitions Output transitions
1 81, 80, 75, 69, 68, 63, 57, 56, 51, 45, 44, 39, 31, 27, 23, 19, 15, 11, 3 7, 42 12
2 7, 35 42 41, 12
31 42, 49 50
4 85, 84, 77, 73, 72, 65, 61, 60, 53, 49, 48, 41, 33, 29, 25, 21, 17, 13, 5 54, 42 12
5 9, 37 54, 42 41, 12
6 83, 82, 76, 71, 64, 59, 58, 52, 47, 46, 40, 32, 28, 24, 20, 16, 12, 70, 4 9, 42 12
7 8, 36 9, 42 41, 12
8 79, 78, 74, 67, 66, 62, 55, 54, 50, 43, 42, 38, 30, 26, 22, 18, 14, 10, 2 2, 42 12
9 6, 34 2, 42 41, 12
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obtained using pathway-based clustering) are difﬁcult to
interpret from biological point of view, so in the further
analysis the classical ones will be used.
Results and discussion
The main goal of our research was the formulation of the
model, described above, which possibly most exactly
would reﬂect the metabolism of the iron in the case of
anemia and inﬂammation. In addition, on the basis of the
analysis of the model’s behavior we have attempted to
make some observations concerning transferrin receptor
and hepcidin.
Transferrin receptor
To the best of our knowledge, there is still no single bio-
chemical parameter that is sensitive or speciﬁc enough to
completely describe the distribution of iron in the human
body. The routinely used laboratory tests, such as serum
iron, total iron-binding capacity, transferrin saturation and
serum ferritin are good indicators of the iron available for
the erythropoiesis and for the iron stores but they are
considerably inﬂuenced by a number of non-related con-
ditions, e.g., the acute phase reactions, which may com-
plicate the clinical interpretation of their results and create
an inaccurate picture of the body iron status [30]. In this
situation, one of the proposed parameter that could be
useful enough for the body iron assessment is the soluble
transferrin receptor (sTfR) whose evaluation is an indirect
measure of the quantity of the membrane transferrin
receptor (TfR) [31]. This assumption is based principally
on the observed correlation between the concentration of
the serum receptor molecule complexes with the transferrin
and the ferrokinetic measurements of the erythron trans-
ferrin uptake [32, 33].
On the basis of the analysis of the models’ behavior, we
have attempted to check the inﬂuence of an inﬂammatory
process on the level of TfR, i.e., TfR1 as well as TfR2.
We have veriﬁed that an inﬂammatory process does not
inﬂuence the TfR1 and TfR2 levels (no t-invariants contain
both, the inﬂammatory process (t43) in MCT-set 9 in
t-clusters 4 and 10 and the TfR regulation (t45, t46) in
MCT-set 13 in t-cluster 3). That means that there is no
connection between these two processes in the basic
behavior of the model.
We have also tried to check whether EPO bears on the
TfR concentration. In our model the TfR regulation was
dependent partially on an increased EPO level. We have
disclosed that in every t-invariant, which includes the TfR
regulation (t45, t46), i.e., those of t-cluster 3, there occurs
EPO production (t39), but on the other hand, EPO pro-
duction also appears in t-invariants in which TfR is not
regulated, namely in t-cluster 4 and partly in t-clusters 1
and 2. So, in the model the TfR regulation is correlated to
an increased EPO level. On this basis, we can suggest that
EPO, and also a supplementation of rHuEPO which con-
tributes to an increase of the serum EPO, may inﬂuence the
TfR concentration and because of this the usefulness of
sTfR for assessment of the body iron status in patients
supplemented with rHuEPO has a questionable value. Our
results have supported some previous reports [34] that
rHuEPO intravenous dose administration inﬂuences the
sTfR serum concentration in hemodialyzed patients. Some
of the researchers suggested [34] that the maintenance
rHuEPO administration may not only enhance the eryth-
ropoiesis in the bone marrow but also may contribute to the
serum sTfR concentration increase [35]. Moreover, some
of them implied that EPO itself raises intracellular calcium
[36] that may contribute to an acceleration of the TfR
recycling. EPO may also regulate the rate of the truncation
of TfR from the cell membrane [34]. Other authors infer
that the circulating sTfR levels may be useful in monitoring
the iron status of mHD patients if the doses of rHuEPO are
maintained constantly in those patients who are likely to be
in a steady state erythropoietic stimulation [37, 38].
Another purpose of our study is to explore the factors
determining the TfR1 concentration. Basing on the
behavior of our model, we ascertained that a main factor
affecting the concentration of this receptor was the con-
centration of the iron in the serum. The serum iron con-
centration (high serum iron concentration causes a TfR1
decrease and a TfR2 increase (t45) in MCT-set 13) mainly
inﬂuences the TfR concentration (which is always inde-
pendent of an inﬂammatory process represented in MCT-
set 9, as has been mentioned above). The low serum iron
concentration results in a TfR1 increasing (t46). The level
of the serum iron concentration mainly inﬂuences the TfR
regulation. A changed level of the Tf receptors inﬂuences
the level of free HFE and via that way (in the case of a high
level of TfR2) an increase of the hepcidin synthesis and a
decrease/inhibition of Fpn (t45 and t46 are grouped in
MCT-set 13 together with t47 (free HFE) and t48 (corre-
sponding hepcidin increase with Fpn inhibition), see
Table 3).
We have also attempted to verify the hypothesis that the
TfR1 concentration is a good marker of the erythropoietic
activity in the human body. In our model if TfR1 is down
regulated (included only in t-cluster 3), there is no iron
uptake to pre-erythrocyte and, therefore, there is no hem
synthesis (t20) which is contained in MCT-set 6 and occurs
only in the t-clusters 1 and 2. Looking at this, we may
suggest that the TfR1 serum concentration is a good marker
of the erythropoietic activity.
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Another question, which we would like to answer, is: does
the EPO concentration inﬂuence the hepcidin concentra-
tion? This issue is very important, particularly for the
patients with an ESRD diagnosis with a diminished EPO
production in the kidneys, an undergoing rHuEPO treat-
ment. In our model, there is no connection between a lower
EPO concentration and hepcidin. On the other hand, an
increase of the EPO concentration (t38) depends on a low
serum iron concentration, thus a high EPO concentration
(t39) results in a hepcidin decrease (t40) connected with an
increase of the Fpn (t35) level (the last two ones are
transitions in MCT-set 12). So, on the basis of the behavior
of our model it is difﬁcult to say for certain that the serum
EPO concentration inﬂuences the hepcidin concentration,
but we suggest that it can be the case.
We have also tried to ﬁnd how the concentration of
hepcidin, HFE, and TfR is changing if there is a low serum
Fe level (during an inﬂammatory process). Generally, the
transition t52 (iron consumption which leads to a low iron
level) in MCT-set 2 participates in every t-invariant (except
of the ﬁrst one which does not represent an iron ﬂow
through the net). From the point of view of the t-invariant
calculation, a low iron level is needed in each of the three
ways through the small intestine characterized by the three
iron levels: high, medium, and low. If the serum iron level
is low there is much EPO production (t38/t39) causing a
hepcidin decrease (t40 in MCT-set 12) and a TfR1
increase. In this situation, TfR2 is not synthesized (t46,
MCT-set 13) followed by no free HFE (t47, MCT-set 13),
no corresponding hepcidin increase (t48, MCT-set 13) and
Fpn decrease (t36, MCT-set 12). In Table 7, the discussed
biological conclusions following from the analysis of the
model have been summarized.
We can conclude that the analysis of the behavior of our
Petrinet-basedmodelofthebodyironhomeostasisallowsus
to have the new insight into this complex process. Such an
analysis is an interesting and valuable complement to the
clinicalresearch.Ontheotherhand,itcanalsosuggestsome
properties of the analyzed process which has not been real-
ized previously. Moreover, since the formal model of the
analyzed phenomenon is built on the basis of the current
knowledge in a particular area its analysis can possibly also
lead to a revision of this knowledge in cases when the
obtained results do not agree with those following from
Table 6 Comparison of common transitions between pathway-based
clustering (horizontal clusters 1–9) and classical clustering methods
(vertical clusters 1–10)
123456789
14 4 4 4
24 4 4 4
32 2 2 2
42 2 2 2
52 2 2 2
62 2 2 2
7 21 2121
8 11 1111
93 2
10 1
Numbers in the table are sizes of common t-invariant subsets within
clusters
Table 7 Summary of the biological conclusions following from the analysis of the model behavior
No. Observations Biological conclusions
1 No t-invariants contain both, an inﬂammatory process, i.e., t43 in
MCT-set 9 in t-clusters 4 and 10, and the TfR regulation, i.e., t45
band t46 in MCT-set 13 in t-cluster 3
The inﬂammatory process does not inﬂuence the TfR1 and TfR
levels.
2 In every t-invariant which includes the TfR regulation, i.e., t45 and
t46 in t-cluster 3 there occurs EPO production, i.e., t39. On the
other hand, t39 also appears in t-invariants in which TfR is not
regulated, i.e., in t-cluster 4 and partly in t-clusters 1 and 2.
The TfR regulation was dependant partially on an increased EPO
level.
3 A level of Tf receptors inﬂuences the level of HFE and an increase of
the hepcidin synthesis and a decrease/inhibition of Fpn—t45 and
t46 are grouped in MCT-set 13 together with HFE, i.e., t47 band
hepcidin increase, i.e., t48.
A main factor affecting the concentration of TfR1 is the
concentration of the iron in serum.
4 If TfR1 is down regulated (included only in t-cluster3), there is no
iron uptake to pre-erythrocyte and therefore there is no hem
synthesis, i.e., t20, which is contained in MCT-set 6 and occurs
only in the t-clusters 1 and 2.
The TfR1 serum concentration is a good marker of the erythropoietic
activity.
5 Iron consumption leading to a low iron level, i.e., t52 in MCT-set 2 is
included in every t-invariant except the ﬁrst one, which does not
represent an iron ﬂow through the net.
A low iron level is needed in each of the ways through the small
intestine characterized by the three iron levels, i.e., high, medium,
and low.
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experiment results can be also necessary in same cases). For
example,in[39]itwasfoundthattheserumconcentrationof
TfR is probably not inﬂuenced by EPO concentration but
from our model it follows the opposite conclusion. The
relation betweenthesetwoconcentrations was not explicitly
used for building the model, hence it follows from the
knowledge which was implicitly the basis for the model
construction. The disagreement between the experimental
andthe theoretical(i.e.,theonesfollowing fromtheanalysis
of the model) results suggests the necessity of a revision of
the knowledge of the human body iron homeostasis process
(since it leads to conclusions contradicting the clinical
results) or a veriﬁcation of the clinical experiments. In both
cases, the analysis of the theoretical model of the process
leads to clarifying some of its aspects and better under-
standing this complex biochemical phenomenon. Following
this direction of research, recently we have performed the
newmoreaccuratelaboratorytests(concerningonlypatients
with anemia of chronic disorders) whose results show that
theconclusionsconcerningtherelationshipbetweenTfRand
rHuEPO coming from our model are correct (see ‘‘Valida-
tion of the model’’).
Validation of the model
Materials and methods
In order to validate our model and verify whether the
obtained results are conﬁrmed in lab tests we used data
obtained from 50 patients with end-stage renal disease,
hemodialyzed in the Department of Nephrology, Trans-
plantology and Internal Medicine, at Poznan ´ University of
Medical Sciences. To the analysis, we included only lab
tests results from the patients suffering from anemia of
chronic disorders and treated with rHuEPO. In every
patient, the selected serum parameters, using ELISA-kits,
like iron (Fe), soluble transferrin receptor (sTfR) which
concentration is proportional to the total concentration of
cellular TfR, hepcidin, erythropoietin concentration (EPO)
were assessed. For the evaluation of the inﬂammatory
status, we examined the levels of selected acute phase
proteins, i.e., C-reactive protein (CRP), Interleukin-1 (IL-
1), and Interleukin-6 (IL-6).
All tests were performed according to the manufacture’s
instruction. Ethical approval was obtained from the local
ethics committee before the start of the study and all
patients were asked for their verbal consent before the
blood was taken.
Table 8 The associations between sTfR and selected inﬂammatory
proteins obtained during laboratory tests from patients with anemia of
chronic disorders
Variable CRP IL-1 IL-6
sTfR r =- 0.155 r = 0.0085 r =- 0.2005
p = 0.297 p = 0.955 p = 0.177
CRP C-reactive protein, IL-1 interleukin 1, IL-6 interleukin 6,
r Pearson’s correlation coefﬁcient, p value of the signiﬁcance level
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Fig. 4 The scatter diagram
(with histograms, i.e., the upper
and the right panel, which are a
graphical way of presenting the
empirical distribution
characteristics) shows the
association between sTfR and
rHuEPO. It illustrates the strong
positive correlation
(r = 0.37332, p = 0.01), which
suggests a strong relationship
between these variables. The
solid line indicates the linear
regression, and the dotted line—
the 95% conﬁdence interval.
sTfR soluble transferrin receptor
whose serum concentration is
proportional to the total
concentration of cellular TfR,
rHuEPO mean weekly dose of
recombinant human
erythropoietin, r Pearson’s
correlation coefﬁcient, p value
of the signiﬁcance level
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123We subjected the obtained results for statistical analysis
using Statistica 8.0 (Stat Soft Inc., Tulsa, USA). The sig-
niﬁcance level was assumed to be equal to 0.05.
Analysis of the results of the laboratory tests
The lack of the statistically signiﬁcant correlations (see
Table 8) between sTfR and selected inﬂammatory variables
conﬁrms the results obtained on the basis of the analysis of
the behaviour of our model, i.e., there is no connection
between TfRs (transferrin receptors) and the inﬂammatory
process.
Based on the lab studies, we assessed the impact of
rHuEPO therapy on the concentration of sTfR. We have
obtained results (see Fig. 4) conﬁrming our previous
observations made on the models’ behavior, i.e., the
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Fig. 5 The scatter diagram
(with histograms, i.e., the upper
and the right panel, which are a
graphical way of presenting the
empirical distribution
characteristics) shows the
association between sTfR and
Fe. It illustrates the strong
negative correlation (Spearman
rank correlation coefﬁcient
r =- 0.4284, p = 0.004),
which suggests a strong inverse
relationship between these
variables. The solid line
indicates the linear regression,
and the dotted line—the 95%
conﬁdence interval. sTfR
soluble transferrin receptor
whose serum concentration is
proportional to the total
concentration of cellular TfR,
Fe serum iron, r Pearson’s
correlation coefﬁcient, p value
of the signiﬁcance level
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Fig. 6 The scatter diagram
(with histograms, i.e., the upper
and the right panel, which are a
graphical way of presenting the
empirical distribution
characteristics) shows the
association between hepcidin
and rHuEPO. It illustrates the
strong negative correlation
(Spearman rank correlation
coefﬁcient r =- 0.8368,
p = 0.000), which suggests a
strong inverse relationship
between these variables. The
solid line indicates the linear
regression, and the dotted line—
the 95% conﬁdence interval.
rHuEPO mean weekly dose of
recombinant human
erythropoietin, r Pearson’s
correlation coefﬁcient, p value
of the signiﬁcance level
Bioprocess Biosyst Eng (2011) 34:581–595 593
123existence of a positive correlation between sTfR and dos-
age of rHuEPO.
Furthermore, as well as in our theoretical analysis, we
found in lab analysis the relationship between low levels of
serum iron and high levels of sTfR (Fig. 5). Other detected
dependencies, i.e., between hepcidin and sTfR and also
between serum EPO and hepcidin were in the lab test, not
statistically signiﬁcant, although similar trends like in
behaviour of our model were preserved—an inverse
relationship.
In addition, during the lab tests we conﬁrmed our results
based on the analysis of the model concerning the statis-
tically signiﬁcant existence of a relationship between
serum hepcidin and the dose of rHuEPO (Fig. 6).
Summary
Anemia of chronic disorders is a very complex issue whose
diagnosis is a not well-established procedure. To better
understand this process and its inﬂuence on some other
factors, a mathematical model of the body iron homeostasis
has been built. The model has been formulated in the
language of Petri net theory, which allows for its simula-
tion and precise analysis, which, in turn, allows to answer
some questions. On the basis of the net analyzed in this
paper, we have found that there is no inﬂuence of inﬂam-
mation on the concentration of the transferrin receptor.
Moreover, the results of the model analysis suggest that
erythropoietin and rHuEPO can inﬂuence the transferrin
receptor levels. It was positively veriﬁed that TfR is a good
marker of the erythropoietic activity. Also answers to
questions if EPO inﬂuences the hepcidin concentration and
how the concentration of hepcidin, HFE and TfR is
changing during an inﬂammatory process have been found.
The results obtained from the analysis of the model and the
clinical research complement each other.
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